Note 3 — Supplemental Financial Information

Unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months and six months ended June 30, 2013 were $473 million and $1.013 billion, respectively, and net earnings allocated to common shares for the three months and six months ended June 30, 2012 were $1.711 billion and $2.943 billion, respectively.

Other (income) expense, net, for the six months ended June 30, 2012 includes income of approximately $40 million from the resolution of a contractual agreement. Other, net in Net cash from operating activities for 2012 includes payments of approximately $800 million to settle certain government investigations related to AbbVie’s business operations. Other, net in Net cash from operating activities for 2013 and 2012 includes the effects of contributions to defined benefit plans of approximately $320 million in each period.

The components of long-term investments as of June 30, 2013 and December 31, 2012 are as follows:

	June 30		December 31
(dollars in millions)	2013		2012
Equity securities	$	126	$	213
Other	28		61
Total	$	154	$	274

The reduction in long-term investments from December 31, 2012 to June 30, 2013 is due primarily to the separation of AbbVie on January 1, 2013.